gaudium® IVF
Delivering Motherhood Dreams

August 13, 2026

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001, Maharashtra
Scrip Code – 544709

ISIN: INE0P8B01020

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400051, Maharashtra
Symbol – GAUDIUMIVF

ISIN: INE0P8B01020

Subject: Press Release on Unaudited Financial Results for the Quarter ended June 30, 2026

Dear Sir/Madam

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, please find enclosed Press Release on Unaudited Financial Results for the quarter ended June 30, 2026.

The above is being made available on the Company's website i.e. www.gaudiumivfcentre.com.

This is for your information, records and appropriate dissemination.

Thanking you,

Yours faithfully.

For and on behalf of Gaudium IVF and Women Health Limited
(Formerly known as Gaudium IVF and Women Health Private Limited)

NAVEEN KUMAR
Digitally signed by NAVEEN KUMAR
Date: 2026.08.13 20:20:46 +05'30'

Naveen Kumar
Company Secretary and Compliance Officer
Membership No.: A69788

Encl.: a/a

Gaudium IVF Reports Steady Q1FY27 Revenue

Q1FY27 Revenue stood at ₹19.4 Cr, registering YoY growth of 9.1%

Q1FY27 EBITDA at ₹2.4 Cr; EBITDA Margin at 12.5%

Q1FY27 PAT stood at ₹1.8 Cr.

Commences operations of New IVF Hub at South Extension, New Delhi

Board approves Gaudium Women Hospital, Lucknow

New Delhi, August 13, 2026: Gaudium IVF and Women Health Limited, a leading fertility and women's healthcare platform in India, today announced its unaudited Financial Results for the quarter ended June 30, 2026.

Consolidated Financial Highlights

(In ₹ Crore)

Particulars	Q1FY27	Q1FY26	YoY
Revenue from Operations	**19.4**	**17.8**	**9.13%**
EBITDA	**2.4**	**5.2**	**-52.96%**
EBITDA Margin %	*12.51%*	*29.02%*	*-1651 bps*
Profit After Tax (PAT)*	**1.8**	**3.1**	**-42.27%**
PAT Margin %	*9.17%*	*17.33%*	*-816 bps*

***Note: PAT represents Profit After Tax from continuing operations.**

Key Financial & Operational Highlights

- Q1 FY27 Revenue from operations stood at ₹19.38 Cr as against ₹17.76 Cr in Q1 FY26, a growth of 9.13% YoY driven by higher patient volumes at mature hubs, sustained traction in advanced IVF protocols, and steady contribution from international patients
- Q1 FY27 EBITDA stood at ₹2.42 Cr as against ₹5.15 Cr, declining 52.96% YoY, with EBITDA Margin at 12.51%; led by operating spends ahead of the FY27 hub rollout; including pre-operationalisation costs for South Extension, preparatory expenses for Nagpur and Gurgaon, incremental clinical talent hiring, and SiD/ERICA integration costs with seasonally muted revenue absorption in Q1. Excluding these expansion-related one-off costs, EBITDA would have stood at ~₹5.35 crore with an EBITDA margin of ~27.63%, broadly in line with our steady-state operating profile.
- Q1 FY27 PAT stood at ₹1.8 Cr as against ₹3.1 Cr, a decline of 42.27% YoY, with PAT Margin at 9.17%;
- The Board approved the establishment, development, operation and management of "Gaudium Women Hospital, Lucknow," Uttar Pradesh, through a 30-year land lease (15-year

lock-in), with an estimated project cost of up to ₹15 crore, marking the Company's entry into Uttar Pradesh.

- The Company commenced commercial operations at its new IVF Centre/Hub at South Extension Part-II, New Delhi, the first milestone of its planned 19-centre expansion, featuring the Gaudium Signature Lab with AI-powered embryology tools (SiD and ERICA).

Key Metrics

As on date, the Company expanded its network to 8 hubs and 28 spokes, while delivering a strong clinical pregnancy success rate of 62% on the first IVF attempt

Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF and Women Health Limited, said:

"Q1 FY27, our first full quarter as a listed company, has been a period of measured progress. Revenue grew 9.13% year-on-year, reflecting the resilience of our mature hubs and the steady flow of patients seeking advanced fertility care at Gaudium. Profitability in the quarter, however, was consciously moderated as we chose to invest ahead of our expansion, bringing on board the clinical talent, systems and readiness needed for the ten hubs planned this year. These investments precede the revenue they support, and that is a trade-off we are comfortable making because the runway ahead is significant. IVF Treatment remains the anchor of the business, with our clinical outcomes at over 62% success in the first attempt, and the early impact of our AI-led embryology tools, SiD and ERICA, is already visible in the consistency of embryo selection across our centres.

The quarter also marked meaningful progress on our expansion roadmap. In June, our Board approved the setting up of "Gaudium Women Hospital, Lucknow" through a long-term arrangement, marking our entry into Uttar Pradesh with a full-service women's hospital format at an estimated project cost of up to ₹15 crore. Post the quarter, on July 16, we commenced operations at our new IVF Centre/Hub at South Extension, New Delhi, the first milestone of our planned 19-centre expansion, housing the Gaudium Signature Lab that combines AI-powered embryology, internationally benchmarked laboratory standards and our standardised clinical protocols.

Looking ahead, our focus remains firmly on execution. Of the 10 hubs planned in FY27, one is now operational at South Extension, and the remaining are progressing on track, including one in Delhi-NCR and one at Nagpur, to be followed by 8 new centres in FY28 and 1 in FY29. Alongside physical expansion, we continue to deepen our technology moat through wider deployment of AI-led embryology across our network and further investments in patient experience. With a debt-light balance sheet post-IPO, a clearly funded expansion plan, and an Indian fertility market that remains significantly underpenetrated, we believe Gaudium IVF is well placed to compound growth responsibly and reinforce its leadership in India's rapidly evolving fertility care sector."

About Gaudium IVF and Women Health Limited

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility and women's healthcare provider in India, offering advanced reproductive solutions and holistic care to women and couples. With centres across Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar, Gaudium IVF provides a comprehensive suite of services, including IVF, ICSI, IUI, fertility preservation, infertility treatments, advanced genetic testing, high-risk pregnancy care, and minimally invasive gynecological procedures supported by integrated pregnancy care and 24/7 patient services.

Led by its Chairperson and Managing Director, Dr. Manika Khanna who is an internationally trained infertility specialist, Gaudium IVF combines global expertise with state-of-the-art technology and personalized treatment protocols to deliver trusted clinical outcomes. Committed to ethical, accessible, and patient-centric care, Gaudium IVF also drives impact through the Gaudium Foundation, promoting women's health, empowerment, and equality.

For more information, please contact	
Company: **Gaudium IVF and Women Health Limited** **Mr. Rakesh Kumar Sharma** Chief Financial Officer cfo@gaudiumivfcentre.com	**Investor Relations (IR):** **Adfactors PR Pvt. Ltd.** **Rushabh Shah/ Anand Venugopal** rushabh.shah@adfactorspr.com/ anand.venugopal@adfactorspr.com